CAEP
Synvia is a Brazilian contract research organization in Campinas providing bioequivalence, Phase I clinical trials, and bioanalytical services to 200+ pharmaceutical sponsors, operating the largest analytical park in Latin America with ANVISA, EMA, and FDA alignment.
- Company typePrivate
- Founded2005
- HeadquartersCampíns, Spain
- Headcount251–500
- GTM typeB2B
- OfferingServices
What CAEP does
Synvia (referred to internally as CAEP) is a Brazil-based contract research organization headquartered in Campinas, founded in 2005, providing bioequivalence studies, Phase I clinical trials, and bioanalytical services to pharmaceutical sponsors. It operates what is described as the largest analytical park in Latin America, anchored by 35+ LC-MS/MS systems, a 20,000 m² facility with 200+ beds, and a headcount of 900+ collaborators. The company executes 200+ studies per year, has delivered 2,000+ studies since inception, and serves 200+ pharmaceutical clients across generic-drug, specialty, biologic, vaccine, cannabis, cosmetic, and medical-device sponsors.
The service portfolio spans early-phase clinical pharmacology, bioequivalence, bioanalytical method development and validation, and Phase II-IV clinical research, supported by a library of 500+ validated bioanalytical methods. Operations are aligned to ANVISA, EMA, and FDA regulatory frameworks, enabling study outputs to support registration submissions across the Americas, Europe, and other regulated markets. Synvia's go-to-market is project-based B2B clinical and analytical services priced per study, with revenue mechanics driven by protocol complexity, sample volume, and bioanalytical throughput rather than subscription or platform pricing.
The business model is asset-heavy and capacity-driven: revenue scales with bed utilization, instrument uptime, and concurrent study execution. The company's positioning — multi-regulatory compliance plus concentrated analytical capacity — targets multinational sponsors seeking a single LatAm site for registration-enabling studies, while the diversified vertical mix (biologics, vaccines, cannabis, cosmetics, devices) provides optionality against any single therapeutic segment's downturn.
CAEP firmographics
Firmographics- Name
- CAEP
- Legal name
- Synvia
- Website
- https://caeplab.com.br
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Synvia is a Brazilian contract research organization in Campinas providing bioequivalence, Phase I clinical trials, and bioanalytical services to 200+ pharmaceutical sponsors, operating the largest analytical park in Latin America with ANVISA, EMA, and FDA alignment.
- Ownership category
- akta.pro rank
CAEP industry classification
Industry- Product category
- Contract Research Organization (CRO) / Pharmaceutical Clinical Research Services
- NAICS
- Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)
Keywords
Where CAEP is headquartered
LocationHeadquarters
- HQ city
- Campíns
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
CAEP business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Bioequivalence Studies: Clinical research services conducting bioequivalence studies for generic and similar drugs in healthy participants and patients, compliant with ANVISA, EMA, and FDA regulatory standards
- Phase I Clinical Trials (PK/PD): Early-phase clinical research services including pharmacokinetic and pharmacodynamic studies for pharmaceutical development
- Bioanalytical Services: Laboratory analysis services including method development, validation, and sample analysis using advanced spectrometry equipment
- Regulatory Support Services: Technical and scientific support for pharmaceutical sponsors including regulatory submissions, CTD dossier preparation, and international registration documentation
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
CAEP product offering
Product offeringCore offering
CAEP operates a Contract Research Organization (CRO) that conducts bioequivalence studies and Phase I (PK/PD) clinical trials for the pharmaceutical industry. Services span clinical research (Phases I-IV), bioanalytical laboratory analysis, and regulatory support for generic and similar drug registration under ANVISA, EMA, and FDA standards. The company integrates a 20,000 m² clinical unit with an in-house bioanalytical laboratory housing 35+ LC-MS/MS systems to deliver end-to-end drug development and registration support.
Product overview
Synvia is a pharmaceutical solutions company offering end-to-end services for the pharmaceutical industry, operating as a unified platform combining clinical research and bioanalytical capabilities. The portfolio includes core bioequivalence and Phase I clinical studies (PK/PD), CRO services, analytical services, and clinical research (Phases I-IV), all aligned with ANVISA, EMA, and FDA regulatory standards. Specialized study types encompass biological medicines/biosimilars, medicinal cannabis, modified-release formulations, multiple doses, topical corticosteroids, and primary dermal irritability testing. Infrastructure includes an integrated 20,000 m² clinical unit with 200+ beds across 4 adaptable layouts and a bioanalytical laboratory with 100,000+ sample capacity/month, comprising the largest mass spectrometry analytical park in Latin America.
Differentiator
Problem solved
Functional benefit
Products and services
- Bioequivalence and Phase I Clinical Studies (PK/PD) Core clinical research offering: bioequivalence studies for generic and similar medications, plus Phase I pharmacokinetic/pharmacodynamic (PK/PD) studies, conducted in compliance with ANVISA, EMA, and FDA standards for pharmaceutical industry sponsors.
- Contract Research Organization (CRO) Services Full CRO services providing technical and scientific support for pharmaceutical sponsors throughout all stages of clinical studies, including project planning, protocol design, study conduct, and final reporting.
- Analytical Services Bioanalytical laboratory services including method development and validation, sample analysis, and pharmaceutical equivalence studies for pharmaceutical sponsors.
- Clinical Research (Phases I to IV) Broader clinical research offering covering Phase I through Phase IV clinical trials, leveraging integrated clinical and bioanalytical capabilities for pharmaceutical sponsors.
- Pharmaceutical Equivalence Studies Pharmaceutical equivalence studies and safety/reliability assessments supporting generic and similar medication development and registration.
- Harmonized Regulatory Studies Globally harmonized bioequivalence studies with protocols aligned to ANVISA, EMA, and FDA standards, including standardized methods and global documentation for international drug registration.
- Biological Medicines and Biosimilars Studies Specialized clinical studies for biological medicines and biosimilars addressing complex therapeutic molecules for pharmaceutical sponsors.
- Medicinal Cannabis Studies Specialized clinical research and bioequivalence studies involving medicinal cannabis products for pharmaceutical sponsors.
- Modified Release Formulation Studies Specialized clinical study offering for development and evaluation of modified-release medications in pharmacokinetic studies.
- Multiple Dose Pharmacokinetic Studies Specialized clinical protocols for multiple-dose pharmacokinetic evaluation and steady-state drug behavior assessment.
- Topical Corticosteroid Studies Specialized dermatological studies and topical corticosteroid efficacy evaluation in clinical research for pharmaceutical sponsors.
- Primary Dermal Irritability Testing Specialized primary dermal irritability testing for dermatological safety assessment in clinical studies.
Quantifiable outcome
- 200+ studies conducted per year with consolidated infrastructure
- +2 more outcomes
Companies that use CAEP
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
CAEP technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
CAEP partnerships and signals
Strategic signalScale indicators11 records
Recent moves5 records
Expansion highlights5 records
CAEP competitors and assessment
Company assessmentBroad incumbents
- WuXi AppTec: Global CRO/CDMO with bioanalytical and clinical research capabilities including bioequivalence for generics. Increasingly competing for LatAm and global generics sponsor work that Synvia targets.
- IQVIA: World's largest CRO offering Phase I-IV clinical research and bioanalytical services globally. Overlaps with Synvia's clinical and bioanalytical offerings but with far broader geographic footprint and sponsor relationships.
- ICON plc: Global CRO providing Phase I-IV clinical research services. Direct competitor in early-phase clinical research with Synvia, though operates at much larger scale and global reach.
- Syneos Health: Global CRO offering clinical and bioanalytical services including Phase I and bioequivalence. Comparable in service scope but with broader therapeutic area coverage and sponsor relationships.
- Charles River Laboratories: Major CRO providing preclinical, clinical, and bioanalytical services including early-stage drug development. Comparable in bioanalytical capabilities and Phase I capacity but much broader service portfolio.
- Eurofins Scientific: Global life sciences testing giant with extensive bioanalytical and pharmaceutical services. Highly comparable to Synvia's bioanalytical lab and bioequivalence offerings, but operates at much larger scale across multiple geographies and service lines.
Direct peers
- Worldwide Clinical Trials: Mid-sized global CRO specializing in early-phase clinical research and bioanalytical services. Comparable in scope and scale to Synvia's Phase I and bioanalytical offerings for pharmaceutical sponsors.
- Frontage Laboratories: Bioanalytical and CRO services provider with strong bioequivalence, PK/PD, and bioanalytical method development capabilities. Closely comparable to Synvia's core offerings for generic drug developers.
- Inotiv: Preclinical and bioanalytical CRO with bioequivalence and toxicology services. Comparable in scientific capabilities and target customer base of pharmaceutical generics developers.
Regional players
- Allergisa Pesquisa Dermato-Cosmética: Brazilian CRO with dermatological and cosmetic clinical research capabilities. Regional peer overlapping with Synvia on certain topical/dermatological bioequivalence studies in the Brazilian market.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CAEP social profiles
Digital presenceCAEP financial estimates
Financial estimateRevenue estimate
Valuation estimate
CAEP leadership team
Management profileNumber of profiles
Profiles1 record
CAEP funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CAEP M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CAEP
What does CAEP do?
CAEP operates a Contract Research Organization (CRO) that conducts bioequivalence studies and Phase I (PK/PD) clinical trials for the pharmaceutical industry. Services span clinical research (Phases I-IV), bioanalytical laboratory analysis, and regulatory support for generic and similar drug registration under ANVISA, EMA, and FDA standards. The company integrates a 20,000 m² clinical unit with an in-house bioanalytical laboratory housing 35+ LC-MS/MS systems to deliver end-to-end drug development and registration support.
Is CAEP a public or private company?
CAEP is a private company. It is classified as unknown and is currently operating.
When was CAEP founded?
CAEP was founded in 2005. It employs 251 to 500 people.
Where is CAEP based?
CAEP is headquartered in Campíns, Spain, in the Europe region.
How does CAEP make money?
Four revenue lines are on record. Bioequivalence Studies are the primary driver. The others are phase I Clinical Trials (PK/PD), bioanalytical Services and regulatory Support Services.
Who are CAEP's main competitors?
Broad incumbents on record are WuXi AppTec, IQVIA, ICON plc, Syneos Health, Charles River Laboratories and Eurofins Scientific. Direct peers are Worldwide Clinical Trials, Frontage Laboratories and Inotiv. Allergisa Pesquisa Dermato-Cosmética is listed as a regional player.
Does CAEP have an API?
No public API is recorded for CAEP.
What industry is CAEP in?
CAEP's product category is Contract Research Organization (CRO) / Pharmaceutical Clinical Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 5417 and its SIC code is 8731.